{"gene":"ACAD9","run_date":"2026-06-09T22:02:37","timeline":{"discoveries":[{"year":2002,"finding":"ACAD9 encodes a novel acyl-CoA dehydrogenase (ninth member of the ACAD family) with dehydrogenase enzymatic activity on palmitoyl-CoA (C16:0) and stearoyl-CoA (C18:0), confirmed by enzymatic assay of recombinant protein.","method":"Enzymatic assay of recombinant ACAD9 protein; cloning and sequence analysis identifying ACAD family signatures","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro enzymatic assay of recombinant protein, single lab, single method","pmids":["12359260"],"is_preprint":false},{"year":2007,"finding":"ACAD9 demonstrates maximum catalytic activity with unsaturated long-chain acyl-CoAs; despite overlapping substrate specificity with VLCAD, ACAD9 and VLCAD cannot compensate for each other in vivo, indicating two independently regulated functional pathways for long-chain fat metabolism.","method":"Biochemical substrate specificity assays; patient fibroblast/tissue studies showing distinct acylcarnitine profiles; ACAD9 mRNA/protein defect characterization in patients","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple patient cases and biochemical assays in a single lab confirming non-redundancy with VLCAD","pmids":["17564966"],"is_preprint":false},{"year":2010,"finding":"ACAD9 is required for mitochondrial respiratory chain complex I assembly; pathogenic ACAD9 mutations cause isolated complex I deficiency, and re-expression of wild-type ACAD9 in patient-derived fibroblasts corrects the complex I defect.","method":"Whole-exome sequencing to identify mutations; complementation of complex I defect by wild-type ACAD9 expression in patient fibroblasts","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional complementation in patient cells replicated across multiple independent patients and labs","pmids":["21057504"],"is_preprint":false},{"year":2010,"finding":"A homozygous ACAD9 mutation (R532W) causes complex I deficiency; wild-type but not mutant ACAD9 restores complex I activity when transduced into patient fibroblasts, confirming the essential role of ACAD9 in complex I function. Riboflavin supplementation improved complex I activity.","method":"Homozygosity mapping; lentiviral transduction complementation assay in patient fibroblasts with wild-type vs. mutant ACAD9; protein modelling","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementation experiment distinguishing wild-type from mutant, replicated in independent patient","pmids":["20929961"],"is_preprint":false},{"year":2013,"finding":"Catalytically inactive ACAD9 provides partial-to-complete rescue of complex I biogenesis in ACAD9-deficient cells and is incorporated into high-molecular-weight complex I assembly intermediates, demonstrating that ACAD9 enzymatic activity is not required for its complex I assembly chaperone function.","method":"Knockdown/complementation in ACAD9-deficient fibroblasts using catalytically inactive ACAD9 mutant; BN-PAGE analysis of assembly intermediates; acylcarnitine profiling","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis of catalytic residues combined with assembly intermediate analysis and functional rescue, single lab with multiple orthogonal methods","pmids":["24158852"],"is_preprint":false},{"year":2013,"finding":"ACAD9 knockdown in VLCAD-deficient fibroblasts revealed that ACAD9 is responsible for production of C14:1-carnitine from oleate and C12-carnitine from palmitate, explaining obscure acylcarnitine species used to diagnose VLCAD deficiency.","method":"Stable knockdown in VLCAD-deficient fibroblasts; acylcarnitine profiling upon fatty acid loading","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown with specific metabolite readout, single lab","pmids":["24158852"],"is_preprint":false},{"year":2015,"finding":"ACAD9 plays a physiological role in long-chain fatty acid oxidation in cells expressing high ACAD9 levels (e.g., HEK293 cells, liver, neurons); ACAD9 knockout in HEK293 cells impaired both long-chain fatty acid oxidation and complex I activity, both rescued by wild-type ACAD9. Residual ACAD enzymatic activity of patient mutations inversely correlates with clinical severity.","method":"ACAD9 knockout in HEK293 cells; fatty acid oxidation flux assays; complementation with wild-type ACAD9; prokaryotic expression system to measure ACAD activity of 16 pathogenic mutations; correlation analysis with patient phenotype severity","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — KO with defined biochemical phenotype rescued by WT, plus in vitro enzymatic assay of 16 mutations correlated with clinical data; multiple orthogonal methods in one study","pmids":["25721401"],"is_preprint":false},{"year":2021,"finding":"ACAD9 forms a ternary complex with ECSIT and NDUFAF1 as the core mitochondrial complex I assembly complex. ACAD9 binds the carboxy-terminal half of ECSIT, while NDUFAF1 binds the amino-terminal half. Binary ACAD9/ECSIT or NDUFAF1/ECSIT complexes are unstable and aggregate, whereas the ternary complex is soluble and highly stable. ECSIT binding occurs at the ETF binding site in the amino-terminal domain of ACAD9, resulting in loss of FAD and enzymatic activity, demonstrating that ACAD9's two functions (FAO and complex I assembly) are mutually exclusive.","method":"Protein binding studies (binary and ternary complex formation); small-angle X-ray scattering (SAXS); molecular modelling; FAD release and enzymatic activity assays; mapping of 42 pathogenic mutations onto homology model","journal":"iScience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution of ternary complex with structural (SAXS) and enzymatic validation, multiple orthogonal methods in one study","pmids":["34646991"],"is_preprint":false},{"year":2021,"finding":"Cardiac-specific ACAD9 knockout mice develop severe neonatal cardiomyopathy and die by 17 days; ECSIT protein levels are significantly reduced in the absence of ACAD9, confirming that ACAD9 is required to stabilize ECSIT in the complex I assembly pathway. Muscle-specific ACAD9 knockout mice are viable but exhibit muscle weakness.","method":"Cre-lox tissue-specific knockout mouse models; Western blot for ECSIT; in vitro mitochondrial function assays; histological analysis","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with defined cardiac and muscular phenotypes plus mechanistic link to ECSIT stabilization, multiple tissues examined","pmids":["34556413"],"is_preprint":false},{"year":2025,"finding":"ACAD9 preserves electron transport chain (complex I) integrity and regulates linoleic acid metabolism for energy production and ROS mitigation in ovarian cancer cells; ACAD9 loss triggers mitochondrial respiratory collapse, ROS accumulation, and redirects linoleic acid flux from β-oxidation toward membrane lipid biosynthesis, increasing polyunsaturated fatty acid incorporation and promoting ferroptosis.","method":"In vivo CRISPR/Cas9 genome-wide knockout screen in orthotopic mouse model; multi-omics (metabolomics, lipidomics, transcriptomics); ACAD9 KO mechanistic studies in cancer cell lines","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo CRISPR screen plus multi-omics integration, single lab","pmids":["40618880"],"is_preprint":false},{"year":2022,"finding":"Expression of ACAD9 V546M variant in cell lines reduces mitochondrial complex I activity by over 50% without affecting the total amount of respiratory chain complexes, indicating this variant specifically impairs complex I activity rather than complex assembly or stability.","method":"Molecular cloning and expression of ACAD9 V546M variant in cell line; mitochondrial respiration assays; ATP production measurement; BN-PAGE/SDS-PAGE for OXPHOS complex composition","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct functional expression with mutagenesis and respiration assay, single lab, single variant studied","pmids":["40806260"],"is_preprint":false}],"current_model":"ACAD9 is a dual-function mitochondrial flavoenzyme: it catalyzes α,β-dehydrogenation of long-chain acyl-CoA esters in fatty acid β-oxidation (with highest activity toward unsaturated long-chain substrates), and serves as an essential chaperone/assembly factor for mitochondrial respiratory chain Complex I by forming a stable ternary complex with ECSIT and NDUFAF1; ECSIT binding at the ETF-binding site of ACAD9 displaces FAD and abolishes enzymatic activity, making the two functions mutually exclusive, while pathogenic mutations cause Complex I deficiency whose severity correlates inversely with residual FAO enzymatic activity."},"narrative":{"mechanistic_narrative":"ACAD9 is a mitochondrial flavoenzyme with dual, mutually exclusive functions: as an acyl-CoA dehydrogenase in long-chain fatty acid β-oxidation and as an essential assembly factor for respiratory chain Complex I [PMID:12359260, PMID:21057504, PMID:34646991]. As an enzyme, it catalyzes α,β-dehydrogenation of long-chain acyl-CoA esters, with maximal activity toward unsaturated long-chain substrates, and contributes physiologically to fatty acid oxidation in high-expressing tissues such as liver and neurons; this activity is non-redundant with VLCAD and generates specific acylcarnitine species (C14:1 from oleate, C12 from palmitate) [PMID:12359260, PMID:17564966, PMID:24158852, PMID:25721401]. Independently of its catalytic activity, ACAD9 functions as a Complex I assembly chaperone, since catalytically inactive ACAD9 still rescues Complex I biogenesis and is incorporated into high-molecular-weight assembly intermediates [PMID:24158852]. ACAD9 executes this role by forming a stable, soluble ternary complex with ECSIT and NDUFAF1, binding the C-terminal half of ECSIT while NDUFAF1 binds its N-terminal half; ECSIT binds at the ETF-binding site of ACAD9, displacing FAD and abolishing dehydrogenase activity, which explains the mutual exclusivity of the two functions [PMID:34646991]. ACAD9 also stabilizes ECSIT protein in vivo [PMID:34556413]. Pathogenic ACAD9 mutations cause isolated Complex I deficiency that is corrected by wild-type but not mutant ACAD9, with clinical severity correlating inversely with residual enzymatic activity [PMID:21057504, PMID:20929961, PMID:25721401].","teleology":[{"year":2002,"claim":"Established ACAD9 as a bona fide acyl-CoA dehydrogenase, defining its molecular activity before any role in disease was known.","evidence":"Cloning and in vitro enzymatic assay of recombinant ACAD9 on palmitoyl-CoA and stearoyl-CoA","pmids":["12359260"],"confidence":"Medium","gaps":["Single in vitro assay does not establish in vivo substrate preference","No structural or cofactor characterization","No link to physiology or disease"]},{"year":2007,"claim":"Showed ACAD9 has distinct, non-redundant function in long-chain fat metabolism, ruling out simple compensation by VLCAD despite overlapping substrate range.","evidence":"Biochemical substrate specificity assays plus patient fibroblast/tissue acylcarnitine profiling","pmids":["17564966"],"confidence":"Medium","gaps":["Mechanistic basis of non-redundancy unresolved at this stage","No molecular partner identified","Single-lab patient series"]},{"year":2010,"claim":"Reassigned ACAD9 as an essential Complex I assembly factor, demonstrating a function beyond fatty acid oxidation through restoration of Complex I in patient cells.","evidence":"Exome sequencing/homozygosity mapping with wild-type vs mutant complementation in patient fibroblasts; riboflavin response","pmids":["21057504","20929961"],"confidence":"High","gaps":["Did not separate enzymatic from assembly contributions","Molecular partners in assembly unknown","Mechanism of Complex I rescue undefined"]},{"year":2013,"claim":"Resolved whether catalysis is needed for the chaperone role, showing the two functions are separable, and pinpointed which acylcarnitine species ACAD9 generates.","evidence":"Catalytically inactive ACAD9 complementation with BN-PAGE assembly-intermediate analysis; knockdown in VLCAD-deficient fibroblasts with acylcarnitine profiling","pmids":["24158852"],"confidence":"High","gaps":["Identity of assembly partners still not defined","Structural basis of incorporation into intermediates unknown"]},{"year":2015,"claim":"Demonstrated ACAD9 contributes physiologically to long-chain fatty acid oxidation and that residual enzymatic activity of mutations predicts clinical severity, unifying the enzyme and disease readouts.","evidence":"ACAD9 knockout in HEK293 cells with FAO flux and Complex I assays; prokaryotic enzymatic assay of 16 pathogenic mutations correlated with patient severity","pmids":["25721401"],"confidence":"High","gaps":["Tissue-level FAO contribution in vivo not directly measured","Correlation does not establish causal mechanism per mutation"]},{"year":2021,"claim":"Provided the structural and biochemical basis for mutual exclusivity, defining the ACAD9-ECSIT-NDUFAF1 ternary assembly complex and how ECSIT binding displaces FAD.","evidence":"Reconstitution of binary/ternary complexes, SAXS and modelling, FAD release and enzymatic assays, mapping of 42 mutations","pmids":["34646991"],"confidence":"High","gaps":["High-resolution structure of the ternary complex not determined","Dynamics of switching between FAO and assembly states in cells unresolved"]},{"year":2021,"claim":"Established the in vivo physiological requirement and tissue-specificity of ACAD9 and confirmed its role in stabilizing ECSIT.","evidence":"Cardiac- and muscle-specific Cre-lox knockout mice with phenotyping, mitochondrial assays, and ECSIT Western blot","pmids":["34556413"],"confidence":"High","gaps":["Mechanism of tissue-specific severity differences unexplained","Relative contribution of FAO vs assembly loss to cardiac phenotype not dissected"]},{"year":2022,"claim":"Identified a variant (V546M) that impairs Complex I activity without altering complex amount, indicating ACAD9 can affect Complex I function beyond assembly/stability.","evidence":"Expression of V546M variant in cells with respiration, ATP, and BN-PAGE/SDS-PAGE assays","pmids":["40806260"],"confidence":"Medium","gaps":["Single variant in single lab","Mechanism by which activity is impaired without assembly defect unknown"]},{"year":2025,"claim":"Extended ACAD9 function to redox and lipid homeostasis, showing its loss redirects linoleic acid flux and promotes ferroptosis in cancer cells.","evidence":"In vivo genome-wide CRISPR screen in orthotopic ovarian cancer model with multi-omics and KO mechanistic studies","pmids":["40618880"],"confidence":"Medium","gaps":["Single-lab/single-cancer-context study","Direct vs indirect role in linoleic acid handling not separated from Complex I collapse"]},{"year":null,"claim":"How cells regulate the switch between ACAD9's enzymatic and assembly states, and a high-resolution structure of the ternary assembly complex, remain open.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution ternary complex structure","Regulatory determinants of FAO-vs-assembly partitioning in vivo unknown","Mechanism of variant-specific Complex I activity loss undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[4,7]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2,6,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,6]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[2,4,7]}],"complexes":["ACAD9-ECSIT-NDUFAF1 complex I assembly complex"],"partners":["ECSIT","NDUFAF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H845","full_name":"Complex I assembly factor ACAD9, mitochondrial","aliases":["Acyl-CoA dehydrogenase family member 9","ACAD-9"],"length_aa":621,"mass_kda":68.8,"function":"Together with NDUFAF1 and ECSIT, forms part of the mitochondrial complex I (MCIA),which is required for the biogenesis of respiratory Complex I (CI) and is therefore crucial for the activation of the oxidative phosphorylation system (PubMed:20816094, PubMed:24158852, PubMed:32320651, PubMed:38086790). ECSIT binding triggers a large conformational change, switching ACAD9 from a fatty acid oxidation (FAO) enzyme to a CI assembly factor (PubMed:38086790). The function in CI assembly is independent of the FAO activity of the protein (PubMed:24158852). As FAO enzyme, it catalyzes the first step in FAO, which consists in the proR-proR stereospecific alpha, beta-dehydrogenation of fatty acyl-CoA thioesters using the electron transfer flavoprotein (ETF) as their physiologic electron acceptor, resulting in the formation of trans-2-enoyl-CoA ((2E)-enoyl-CoA) (PubMed:12359260, PubMed:16020546, PubMed:17564966, PubMed:21237683, PubMed:24158852). Its preferred substrates are both saturated and unsaturated long-chain acyl-CoA substrates, with optimum activity toward the latter (PubMed:12359260, PubMed:16020546, PubMed:17564966, PubMed:21237683, PubMed:24158852). Among the different mitochondrial acyl-CoA dehydrogenases, its FAO activity overlaps with that of ACADV and ACADL, but plays a primary role in tissues where it is the main long-chain ACAD expressed, such as the central nervous system (PubMed:16020546, PubMed:17564966, PubMed:24158852)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/Q9H845/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACAD9","classification":"Not Classified","n_dependent_lines":180,"n_total_lines":1208,"dependency_fraction":0.1490066225165563},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACAD9","total_profiled":1310},"omim":[{"mim_id":"615533","title":"TRANSMEMBRANE PROTEIN 126B; TMEM126B","url":"https://www.omim.org/entry/615533"},{"mim_id":"611126","title":"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 20; MC1DN20","url":"https://www.omim.org/entry/611126"},{"mim_id":"611103","title":"ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9; ACAD9","url":"https://www.omim.org/entry/611103"},{"mim_id":"252010","title":"MITOCHONDRIAL COMPLEX I DEFICIENCY, NUCLEAR TYPE 1; MC1DN1","url":"https://www.omim.org/entry/252010"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ACAD9"},"hgnc":{"alias_symbol":["NPD002","MGC14452"],"prev_symbol":[]},"alphafold":{"accession":"Q9H845","domains":[{"cath_id":"1.10.540.10","chopping":"57-170","consensus_level":"medium","plddt":96.7359,"start":57,"end":170},{"cath_id":"2.40.110.10","chopping":"176-293","consensus_level":"medium","plddt":97.3331,"start":176,"end":293},{"cath_id":"1.20.140.10","chopping":"300-420","consensus_level":"medium","plddt":95.95,"start":300,"end":420},{"cath_id":"1.20.140.10","chopping":"428-594","consensus_level":"high","plddt":93.5625,"start":428,"end":594}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H845","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H845-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H845-F1-predicted_aligned_error_v6.png","plddt_mean":91.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACAD9","jax_strain_url":"https://www.jax.org/strain/search?query=ACAD9"},"sequence":{"accession":"Q9H845","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H845.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H845/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H845"}},"corpus_meta":[{"pmid":"21057504","id":"PMC_21057504","title":"Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21057504","citation_count":187,"is_preprint":false},{"pmid":"17564966","id":"PMC_17564966","title":"A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency.","date":"2007","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17564966","citation_count":98,"is_preprint":false},{"pmid":"20929961","id":"PMC_20929961","title":"Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene.","date":"2010","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20929961","citation_count":93,"is_preprint":false},{"pmid":"12359260","id":"PMC_12359260","title":"Cloning and functional characterization of ACAD-9, a novel member of human acyl-CoA dehydrogenase family.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12359260","citation_count":75,"is_preprint":false},{"pmid":"24158852","id":"PMC_24158852","title":"ACAD9, a complex I assembly factor with a moonlighting function in fatty acid oxidation deficiencies.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24158852","citation_count":57,"is_preprint":false},{"pmid":"30025539","id":"PMC_30025539","title":"Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective?","date":"2018","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30025539","citation_count":57,"is_preprint":false},{"pmid":"25721401","id":"PMC_25721401","title":"Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25721401","citation_count":45,"is_preprint":false},{"pmid":"23836383","id":"PMC_23836383","title":"Mitochondrial encephalomyopathy due to a novel mutation in ACAD9.","date":"2013","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23836383","citation_count":40,"is_preprint":false},{"pmid":"23996478","id":"PMC_23996478","title":"A Patient with Complex I Deficiency Caused by a Novel ACAD9 Mutation Not Responding to Riboflavin Treatment.","date":"2013","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/23996478","citation_count":28,"is_preprint":false},{"pmid":"26826406","id":"PMC_26826406","title":"Neonatal multiorgan failure due to ACAD9 mutation and complex I deficiency with mitochondrial hyperplasia in liver, cardiac myocytes, skeletal muscle, and renal tubules.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26826406","citation_count":27,"is_preprint":false},{"pmid":"26669660","id":"PMC_26669660","title":"High incidence and variable clinical outcome of cardiac hypertrophy due to ACAD9 mutations in childhood.","date":"2015","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/26669660","citation_count":25,"is_preprint":false},{"pmid":"34646991","id":"PMC_34646991","title":"Molecular mechanism of interactions between ACAD9 and binding partners in mitochondrial respiratory complex I assembly.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34646991","citation_count":24,"is_preprint":false},{"pmid":"27233227","id":"PMC_27233227","title":"Evidence of a wide spectrum of cardiac involvement due to ACAD9 mutations: Report on nine patients.","date":"2016","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27233227","citation_count":23,"is_preprint":false},{"pmid":"28070495","id":"PMC_28070495","title":"An atypical presentation of ACAD9 deficiency: Diagnosis by whole exome sequencing broadens the phenotypic spectrum and alters treatment approach.","date":"2016","source":"Molecular genetics and metabolism reports","url":"https://pubmed.ncbi.nlm.nih.gov/28070495","citation_count":12,"is_preprint":false},{"pmid":"34556413","id":"PMC_34556413","title":"Development and characterization of a mouse model for Acad9 deficiency.","date":"2021","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34556413","citation_count":11,"is_preprint":false},{"pmid":"40618880","id":"PMC_40618880","title":"Metabolic gatekeeper ACAD9 coordinates linoleic acid metabolism and redox homeostasis via mitochondrial complex I to drive ovarian cancer progression.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/40618880","citation_count":9,"is_preprint":false},{"pmid":"37388727","id":"PMC_37388727","title":"Immunodeficiency with susceptibility to lymphoma with complex genotype affecting energy metabolism (FBP1, ACAD9) and vesicle trafficking (RAB27A).","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37388727","citation_count":9,"is_preprint":false},{"pmid":"26475292","id":"PMC_26475292","title":"Lethal Neonatal Progression of Fetal Cardiomegaly Associated to ACAD9 Deficiency.","date":"2015","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/26475292","citation_count":9,"is_preprint":false},{"pmid":"27438479","id":"PMC_27438479","title":"Severe defect in mitochondrial complex I assembly with mitochondrial DNA deletions in ACAD9-deficient mild myopathy.","date":"2017","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/27438479","citation_count":9,"is_preprint":false},{"pmid":"35708204","id":"PMC_35708204","title":"Molecular characteristics of the multi-functional FAO enzyme ACAD9 illustrate the importance of FADH2 /NADH ratios for mitochondrial ROS formation.","date":"2022","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35708204","citation_count":9,"is_preprint":false},{"pmid":"28279569","id":"PMC_28279569","title":"Lifetime exercise intolerance with lactic acidosis as key manifestation of novel compound heterozygous ACAD9 mutations causing complex I deficiency.","date":"2017","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/28279569","citation_count":9,"is_preprint":false},{"pmid":"28529009","id":"PMC_28529009","title":"Assembly defects of multiple respiratory chain complexes in a child with cardiac hypertrophy associated with a novel ACAD9 mutation.","date":"2017","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28529009","citation_count":9,"is_preprint":false},{"pmid":"37064341","id":"PMC_37064341","title":"Severe Antenatal Hypertrophic Cardiomyopathy Secondary to ACAD9-Related Mitochondrial Complex I Deficiency.","date":"2022","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/37064341","citation_count":7,"is_preprint":false},{"pmid":"20816087","id":"PMC_20816087","title":"Assembling complex I with ACAD9.","date":"2010","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20816087","citation_count":4,"is_preprint":false},{"pmid":"33204590","id":"PMC_33204590","title":"Successful pregnancy in a patient with mitochondrial cardiomyopathy due to ACAD9 deficiency.","date":"2020","source":"JIMD reports","url":"https://pubmed.ncbi.nlm.nih.gov/33204590","citation_count":3,"is_preprint":false},{"pmid":"40806260","id":"PMC_40806260","title":"A Late-Onset and Mild Phenotype of Mitochondrial Complex I Deficiency Due to a Novel Reported Variant Within the ACAD9 Gene.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40806260","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13702,"output_tokens":2788,"usd":0.041463,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10233,"output_tokens":3254,"usd":0.066257,"stage2_stop_reason":"end_turn"},"total_usd":0.10772,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"ACAD9 encodes a novel acyl-CoA dehydrogenase (ninth member of the ACAD family) with dehydrogenase enzymatic activity on palmitoyl-CoA (C16:0) and stearoyl-CoA (C18:0), confirmed by enzymatic assay of recombinant protein.\",\n      \"method\": \"Enzymatic assay of recombinant ACAD9 protein; cloning and sequence analysis identifying ACAD family signatures\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro enzymatic assay of recombinant protein, single lab, single method\",\n      \"pmids\": [\"12359260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ACAD9 demonstrates maximum catalytic activity with unsaturated long-chain acyl-CoAs; despite overlapping substrate specificity with VLCAD, ACAD9 and VLCAD cannot compensate for each other in vivo, indicating two independently regulated functional pathways for long-chain fat metabolism.\",\n      \"method\": \"Biochemical substrate specificity assays; patient fibroblast/tissue studies showing distinct acylcarnitine profiles; ACAD9 mRNA/protein defect characterization in patients\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple patient cases and biochemical assays in a single lab confirming non-redundancy with VLCAD\",\n      \"pmids\": [\"17564966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ACAD9 is required for mitochondrial respiratory chain complex I assembly; pathogenic ACAD9 mutations cause isolated complex I deficiency, and re-expression of wild-type ACAD9 in patient-derived fibroblasts corrects the complex I defect.\",\n      \"method\": \"Whole-exome sequencing to identify mutations; complementation of complex I defect by wild-type ACAD9 expression in patient fibroblasts\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional complementation in patient cells replicated across multiple independent patients and labs\",\n      \"pmids\": [\"21057504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A homozygous ACAD9 mutation (R532W) causes complex I deficiency; wild-type but not mutant ACAD9 restores complex I activity when transduced into patient fibroblasts, confirming the essential role of ACAD9 in complex I function. Riboflavin supplementation improved complex I activity.\",\n      \"method\": \"Homozygosity mapping; lentiviral transduction complementation assay in patient fibroblasts with wild-type vs. mutant ACAD9; protein modelling\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementation experiment distinguishing wild-type from mutant, replicated in independent patient\",\n      \"pmids\": [\"20929961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Catalytically inactive ACAD9 provides partial-to-complete rescue of complex I biogenesis in ACAD9-deficient cells and is incorporated into high-molecular-weight complex I assembly intermediates, demonstrating that ACAD9 enzymatic activity is not required for its complex I assembly chaperone function.\",\n      \"method\": \"Knockdown/complementation in ACAD9-deficient fibroblasts using catalytically inactive ACAD9 mutant; BN-PAGE analysis of assembly intermediates; acylcarnitine profiling\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis of catalytic residues combined with assembly intermediate analysis and functional rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24158852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ACAD9 knockdown in VLCAD-deficient fibroblasts revealed that ACAD9 is responsible for production of C14:1-carnitine from oleate and C12-carnitine from palmitate, explaining obscure acylcarnitine species used to diagnose VLCAD deficiency.\",\n      \"method\": \"Stable knockdown in VLCAD-deficient fibroblasts; acylcarnitine profiling upon fatty acid loading\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown with specific metabolite readout, single lab\",\n      \"pmids\": [\"24158852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ACAD9 plays a physiological role in long-chain fatty acid oxidation in cells expressing high ACAD9 levels (e.g., HEK293 cells, liver, neurons); ACAD9 knockout in HEK293 cells impaired both long-chain fatty acid oxidation and complex I activity, both rescued by wild-type ACAD9. Residual ACAD enzymatic activity of patient mutations inversely correlates with clinical severity.\",\n      \"method\": \"ACAD9 knockout in HEK293 cells; fatty acid oxidation flux assays; complementation with wild-type ACAD9; prokaryotic expression system to measure ACAD activity of 16 pathogenic mutations; correlation analysis with patient phenotype severity\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — KO with defined biochemical phenotype rescued by WT, plus in vitro enzymatic assay of 16 mutations correlated with clinical data; multiple orthogonal methods in one study\",\n      \"pmids\": [\"25721401\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ACAD9 forms a ternary complex with ECSIT and NDUFAF1 as the core mitochondrial complex I assembly complex. ACAD9 binds the carboxy-terminal half of ECSIT, while NDUFAF1 binds the amino-terminal half. Binary ACAD9/ECSIT or NDUFAF1/ECSIT complexes are unstable and aggregate, whereas the ternary complex is soluble and highly stable. ECSIT binding occurs at the ETF binding site in the amino-terminal domain of ACAD9, resulting in loss of FAD and enzymatic activity, demonstrating that ACAD9's two functions (FAO and complex I assembly) are mutually exclusive.\",\n      \"method\": \"Protein binding studies (binary and ternary complex formation); small-angle X-ray scattering (SAXS); molecular modelling; FAD release and enzymatic activity assays; mapping of 42 pathogenic mutations onto homology model\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution of ternary complex with structural (SAXS) and enzymatic validation, multiple orthogonal methods in one study\",\n      \"pmids\": [\"34646991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cardiac-specific ACAD9 knockout mice develop severe neonatal cardiomyopathy and die by 17 days; ECSIT protein levels are significantly reduced in the absence of ACAD9, confirming that ACAD9 is required to stabilize ECSIT in the complex I assembly pathway. Muscle-specific ACAD9 knockout mice are viable but exhibit muscle weakness.\",\n      \"method\": \"Cre-lox tissue-specific knockout mouse models; Western blot for ECSIT; in vitro mitochondrial function assays; histological analysis\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with defined cardiac and muscular phenotypes plus mechanistic link to ECSIT stabilization, multiple tissues examined\",\n      \"pmids\": [\"34556413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ACAD9 preserves electron transport chain (complex I) integrity and regulates linoleic acid metabolism for energy production and ROS mitigation in ovarian cancer cells; ACAD9 loss triggers mitochondrial respiratory collapse, ROS accumulation, and redirects linoleic acid flux from β-oxidation toward membrane lipid biosynthesis, increasing polyunsaturated fatty acid incorporation and promoting ferroptosis.\",\n      \"method\": \"In vivo CRISPR/Cas9 genome-wide knockout screen in orthotopic mouse model; multi-omics (metabolomics, lipidomics, transcriptomics); ACAD9 KO mechanistic studies in cancer cell lines\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo CRISPR screen plus multi-omics integration, single lab\",\n      \"pmids\": [\"40618880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Expression of ACAD9 V546M variant in cell lines reduces mitochondrial complex I activity by over 50% without affecting the total amount of respiratory chain complexes, indicating this variant specifically impairs complex I activity rather than complex assembly or stability.\",\n      \"method\": \"Molecular cloning and expression of ACAD9 V546M variant in cell line; mitochondrial respiration assays; ATP production measurement; BN-PAGE/SDS-PAGE for OXPHOS complex composition\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct functional expression with mutagenesis and respiration assay, single lab, single variant studied\",\n      \"pmids\": [\"40806260\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACAD9 is a dual-function mitochondrial flavoenzyme: it catalyzes α,β-dehydrogenation of long-chain acyl-CoA esters in fatty acid β-oxidation (with highest activity toward unsaturated long-chain substrates), and serves as an essential chaperone/assembly factor for mitochondrial respiratory chain Complex I by forming a stable ternary complex with ECSIT and NDUFAF1; ECSIT binding at the ETF-binding site of ACAD9 displaces FAD and abolishes enzymatic activity, making the two functions mutually exclusive, while pathogenic mutations cause Complex I deficiency whose severity correlates inversely with residual FAO enzymatic activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ACAD9 is a mitochondrial flavoenzyme with dual, mutually exclusive functions: as an acyl-CoA dehydrogenase in long-chain fatty acid β-oxidation and as an essential assembly factor for respiratory chain Complex I [#0, #2, #7]. As an enzyme, it catalyzes α,β-dehydrogenation of long-chain acyl-CoA esters, with maximal activity toward unsaturated long-chain substrates, and contributes physiologically to fatty acid oxidation in high-expressing tissues such as liver and neurons; this activity is non-redundant with VLCAD and generates specific acylcarnitine species (C14:1 from oleate, C12 from palmitate) [#0, #1, #5, #6]. Independently of its catalytic activity, ACAD9 functions as a Complex I assembly chaperone, since catalytically inactive ACAD9 still rescues Complex I biogenesis and is incorporated into high-molecular-weight assembly intermediates [#4]. ACAD9 executes this role by forming a stable, soluble ternary complex with ECSIT and NDUFAF1, binding the C-terminal half of ECSIT while NDUFAF1 binds its N-terminal half; ECSIT binds at the ETF-binding site of ACAD9, displacing FAD and abolishing dehydrogenase activity, which explains the mutual exclusivity of the two functions [#7]. ACAD9 also stabilizes ECSIT protein in vivo [#8]. Pathogenic ACAD9 mutations cause isolated Complex I deficiency that is corrected by wild-type but not mutant ACAD9, with clinical severity correlating inversely with residual enzymatic activity [#2, #3, #6].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established ACAD9 as a bona fide acyl-CoA dehydrogenase, defining its molecular activity before any role in disease was known.\",\n      \"evidence\": \"Cloning and in vitro enzymatic assay of recombinant ACAD9 on palmitoyl-CoA and stearoyl-CoA\",\n      \"pmids\": [\"12359260\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Single in vitro assay does not establish in vivo substrate preference\", \"No structural or cofactor characterization\", \"No link to physiology or disease\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed ACAD9 has distinct, non-redundant function in long-chain fat metabolism, ruling out simple compensation by VLCAD despite overlapping substrate range.\",\n      \"evidence\": \"Biochemical substrate specificity assays plus patient fibroblast/tissue acylcarnitine profiling\",\n      \"pmids\": [\"17564966\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanistic basis of non-redundancy unresolved at this stage\", \"No molecular partner identified\", \"Single-lab patient series\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Reassigned ACAD9 as an essential Complex I assembly factor, demonstrating a function beyond fatty acid oxidation through restoration of Complex I in patient cells.\",\n      \"evidence\": \"Exome sequencing/homozygosity mapping with wild-type vs mutant complementation in patient fibroblasts; riboflavin response\",\n      \"pmids\": [\"21057504\", \"20929961\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Did not separate enzymatic from assembly contributions\", \"Molecular partners in assembly unknown\", \"Mechanism of Complex I rescue undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Resolved whether catalysis is needed for the chaperone role, showing the two functions are separable, and pinpointed which acylcarnitine species ACAD9 generates.\",\n      \"evidence\": \"Catalytically inactive ACAD9 complementation with BN-PAGE assembly-intermediate analysis; knockdown in VLCAD-deficient fibroblasts with acylcarnitine profiling\",\n      \"pmids\": [\"24158852\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Identity of assembly partners still not defined\", \"Structural basis of incorporation into intermediates unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated ACAD9 contributes physiologically to long-chain fatty acid oxidation and that residual enzymatic activity of mutations predicts clinical severity, unifying the enzyme and disease readouts.\",\n      \"evidence\": \"ACAD9 knockout in HEK293 cells with FAO flux and Complex I assays; prokaryotic enzymatic assay of 16 pathogenic mutations correlated with patient severity\",\n      \"pmids\": [\"25721401\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Tissue-level FAO contribution in vivo not directly measured\", \"Correlation does not establish causal mechanism per mutation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided the structural and biochemical basis for mutual exclusivity, defining the ACAD9-ECSIT-NDUFAF1 ternary assembly complex and how ECSIT binding displaces FAD.\",\n      \"evidence\": \"Reconstitution of binary/ternary complexes, SAXS and modelling, FAD release and enzymatic assays, mapping of 42 mutations\",\n      \"pmids\": [\"34646991\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"High-resolution structure of the ternary complex not determined\", \"Dynamics of switching between FAO and assembly states in cells unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established the in vivo physiological requirement and tissue-specificity of ACAD9 and confirmed its role in stabilizing ECSIT.\",\n      \"evidence\": \"Cardiac- and muscle-specific Cre-lox knockout mice with phenotyping, mitochondrial assays, and ECSIT Western blot\",\n      \"pmids\": [\"34556413\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanism of tissue-specific severity differences unexplained\", \"Relative contribution of FAO vs assembly loss to cardiac phenotype not dissected\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified a variant (V546M) that impairs Complex I activity without altering complex amount, indicating ACAD9 can affect Complex I function beyond assembly/stability.\",\n      \"evidence\": \"Expression of V546M variant in cells with respiration, ATP, and BN-PAGE/SDS-PAGE assays\",\n      \"pmids\": [\"40806260\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Single variant in single lab\", \"Mechanism by which activity is impaired without assembly defect unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended ACAD9 function to redox and lipid homeostasis, showing its loss redirects linoleic acid flux and promotes ferroptosis in cancer cells.\",\n      \"evidence\": \"In vivo genome-wide CRISPR screen in orthotopic ovarian cancer model with multi-omics and KO mechanistic studies\",\n      \"pmids\": [\"40618880\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Single-lab/single-cancer-context study\", \"Direct vs indirect role in linoleic acid handling not separated from Complex I collapse\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How cells regulate the switch between ACAD9's enzymatic and assembly states, and a high-resolution structure of the ternary assembly complex, remain open.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No high-resolution ternary complex structure\", \"Regulatory determinants of FAO-vs-assembly partitioning in vivo unknown\", \"Mechanism of variant-specific Complex I activity loss undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [4, 7]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2, 6, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [2, 4, 7]}\n    ],\n    \"complexes\": [\"ACAD9-ECSIT-NDUFAF1 complex I assembly complex\"],\n    \"partners\": [\"ECSIT\", \"NDUFAF1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}